Cytosorbents Corp

CTSOReported to SECin USCIK 0001175151Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 7. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 7
Form 4 lines at Cytosorbents Corp, most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Chan Phillip P.Chief Executive OfficerOpen-market buy$22,6443,774 sharesSep 16, 2026Chan Phillip P.Chief Executive Officer$22,644Buy · Sep 16Open-market buy3,774Sep 16, 2026
Capponi VincentPresident and COOOpen-market buy$1,611273 sharesSep 16, 2026Capponi VincentPresident and COO$1,611Buy · Sep 16Open-market buy273Sep 16, 2026
Capponi VincentPresident and COOOpen-market buy$10,9261,800 sharesSep 16, 2026Capponi VincentPresident and COO$10,926Buy · Sep 16Open-market buy1,800Sep 16, 2026
Sobel Alan D.—Open-market buy$601100 sharesSep 16, 2026Sobel Alan D.$601Buy · Sep 16Open-market buy100Sep 16, 2026
Sobel Alan D.—Open-market buy$3,025500 sharesSep 16, 2026Sobel Alan D.$3,025Buy · Sep 16Open-market buy500Sep 16, 2026